Apogee Therapeutics Inc. has selected a development candidate for its APG-990 program, a subcutaneous half-life extended monoclonal antibody targeting OX40L, initially being developed for atopic dermatitis.
Killer immunoglobulin-like receptor (KIR)-chimeric antigen receptor (CAR) T-cell therapies have previously demonstrated superior performance and functional persistence in solid tumor models, and the mesothelin-specific KIR-CAR T cells, Synkir-110, are now being evaluated in phase I trials by Verismo Therapeutics Inc.
Researchers from the University of Florida have developed a novel mRNA cancer vaccine that aims to reprogram the immune system to target and attack cancer cells effectively. The study led by Elias Sayour reported a new mRNA vaccine design where the mRNA payload was wrapped into a multilamellar vesicle within an onion-like hierarchical structure. The findings were published in the May 9, 2024 issue of Cell.
Raytone Biotechnology Co. Ltd. has described compounds based on oxidative stress and antiamyloid aggregations reported to be useful for the treatment of cataracts and presbyopia.
Zhuhai Yufan Biotechnologies Co. Ltd. has divulged mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer, chronic obstructive pulmonary disease, AIDS, hemolytic anemia, psoriasis, scleroderma, systemic lupus erythematosus and ulcerative colitis, among others.
Allorion Therapeutics (Guangzhou) Co. Ltd. has identified phosphoramidate compounds targeting aldo-keto reductase family 1 member C3 (AKR1C3; 17β-HSD5) reported to be useful for the treatment of cancer.
Norwegian University of Science and Technology (NTNU) has synthesized macrophage colony-stimulating factor 1 receptor (CSF-1R; CD115; c-Fms) inhibitors reported to be useful for the treatment of cancer, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, macular degeneration, osteoarthritis, osteoporosis, rheumatoid arthritis and Alzheimer’s disease, among others.
Université de Montréal has disclosed serine/threonine-protein kinase A-Raf, (ARAF) and/or B-Raf (BRAF) and/or RAF proto-oncogene serine/threonine-protein kinase (c-Raf) inhibitors reported to be useful for the treatment of cancer.
Researchers from Indiana University presented data from a study that aimed to assess the therapeutic potential of interleukin-9 (IL-9) blockade in the context of lung cancer.
At the recently concluded ARVO meeting, Splicebio S.L. presented the first preclinical results on the company’s new candidate, SB-007, for the treatment of Stargardt disease, a rare genetic disease caused by mutations in the ABCA4 gene with no approved treatment on the market.
RSS
